The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

For dividend-seeking investors, a buoyant stock market can be a little annoying. Stock prices rising faster than profits ...

Flush with Trump connections, Ballard Partners is D.C.’s new lobbying powerhouse — and its clients are reaping the benefits.

Novo Nordisk remains the GLP-1 leader with over 65% market share. Read an in-depth BVO stock analysis and why we rate it as a ...

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NOVO NORDISK A/S (NVO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Some would say Eli Lilly just had its Novo Nordisk moment. Analysts mostly agree that the selloff in Lilly shares after the ...

Weight-loss drugs significantly improve health, though they’re also tied to increased spending on other medical care that’s sustained over time, a new study found.

Novo Nordisk shares jumped more than 5% on Friday, extending Thursday’s rally, after Eli Lilly’s obesity pill data fell short ...

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Some studies have linked the popular weight-loss drugs with a potentially higher risk of eye problems and vision loss. Should ...

Novo Nordisk's flagship product is semaglutide. Sold under the names Ozempic and Wegovy, it's one of the leading GLP-1 ...